SLC44A4 and neoplasm: In preclinical studies, IDO1 inhibitors have shown a low tumor burden, and when combined with immune checkpoint therapy, such as anti-PD-L1 and CTL4, tend to provide a synergistic benefit by reducing brain tumor mass and the amount of tumor-infiltrating Tregs while increasing the survival rate of malignant glioma-bearing mice [24].